A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma
Authors:
Open Access
- 21 February 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (5) , 947-952
Abstract
Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin and by down-regulating DNA repair. Thus, combined panobinostat and epirubicin therapy was evaluated to treat refractory sarcoma. Patients with advanced solid tumors were enrolled in a 3 + 3 dose-escalation phase I trial of panobinostat given on days 1, 3, and 5 followed by 75 mg/m2 of epirubicin on day 5 in 21-day cycles, with a dose expansion at maximum tolerated dose (MTD) in 20 sarcoma patients. Peripheral blood mononucleocyte histone acetylation was also evaluated. Forty patients received 20–60 mg panobinostat. Dose-limiting toxicities included thrombocytopenia, febrile neutropenia, and fatigue at 60 mg, defining a panobinostat MTD at 50 mg. Four responses were seen in 37 assessable patients, all after progression on prior topoisomerase II inhibitors. For those with sarcoma, 12 of 20 derived clinical benefit (1 partial response and 11 stable disease, median overall survival 8.3 months), including 8 of 14 previously progressed on topoisomerase II therapy. Treatment benefits correlated with increased histone acetylation and decreased neutrophil count on day 5. Panobinostat and epirubicin treatment is well tolerated and may reverse anthracycline resistance. Changes in histone acetylation and associated decrease in neutrophil count correlated with clinical benefit and warrant investigation as predictive biomarkers. This trial is registered at www.Clinicaltrials.gov, Identifier: NCT00878904.Keywords
Funding Information
- Novartis International AG
- National Cancer Institute
- National Institutes of Health (RO1 1RC1CA145425-01, R01 CA122657)
- Novartis International AG
- National Cancer Institute
- National Institutes of Health (RO1 1RC1CA145425-01, R01 CA122657)
This publication has 25 references indexed in Scilit:
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of CancerFuture Oncology, 2011
- The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapyJournal of Orthopaedic Research, 2010
- Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivoMolecular Cancer, 2010
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive markerBritish Journal of Cancer, 2009
- Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational StudyJournal of Clinical Oncology, 2007
- The Effects of Histone Deacetylase Inhibitors on the Induction of Differentiation in Chondrosarcoma CellsClinical Cancer Research, 2007
- In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesMolecular Cancer Therapeutics, 2005
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Management of Advanced Adult Soft Tissue SarcomaSarcoma, 2003